Patents by Inventor William J. Koopman

William J. Koopman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
    Patent number: 9700618
    Abstract: An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: July 11, 2017
    Assignee: The UAB Research Foundation
    Inventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman
  • ANTIBODY SELECTIVE FOR A TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND RECEPTOR AND USES THEREOF
    Publication number: 20140308288
    Abstract: An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Application
    Filed: March 12, 2014
    Publication date: October 16, 2014
    Inventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman
  • Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor DR5 and uses thereof
    Patent number: 8715668
    Abstract: An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Grant
    Filed: September 17, 2012
    Date of Patent: May 6, 2014
    Assignee: The UAB Research Foundation
    Inventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman
  • Antibody Selective for a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor and Uses Thereof
    Publication number: 20130243780
    Abstract: An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Application
    Filed: September 17, 2012
    Publication date: September 19, 2013
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman
  • Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
    Patent number: 8329180
    Abstract: An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Grant
    Filed: October 10, 2011
    Date of Patent: December 11, 2012
    Assignee: The UAB Research Foundation
    Inventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman
  • ANTIBODY SELECTIVE FOR A TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND RECEPTOR AND USES THEREOF
    Publication number: 20120076792
    Abstract: An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of o the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Application
    Filed: October 10, 2011
    Publication date: March 29, 2012
    Applicant: The UAB Research Foundation
    Inventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman
  • Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
    Patent number: 8067001
    Abstract: An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: November 29, 2011
    Assignee: The UAB Research Foundation
    Inventors: Tong Zhou, Kimishisa Ichikawa, Robert P. Kimberly, William J. Koopman
  • Combinations of antibodies selective for DR5 and other therapeutic agents
    Patent number: 7981421
    Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: July 19, 2011
    Assignee: The UAB Research Foundation
    Inventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman, Jun Ohsumi, Albert F. LoBuglio, Donald J. Buchsbaum
  • Antibody Selective for a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor and Uses Thereof
    Publication number: 20110008324
    Abstract: An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Application
    Filed: June 24, 2010
    Publication date: January 13, 2011
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman
  • COMBINATIONS OF ANTIBODIES SELECTIVE FOR DR5 AND OTHER THERAPEUTIC AGENTS
    Publication number: 20110002887
    Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Application
    Filed: January 13, 2010
    Publication date: January 6, 2011
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventors: Robert P. Kimberly, William J. Koopman, Albert F. LoBuglio, Tong Zhou, Donald J. Buchsbaum, Kimihisa Ichikawa, Jun Ohsumi
  • Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
    Patent number: 7790165
    Abstract: An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Grant
    Filed: June 8, 2007
    Date of Patent: September 7, 2010
    Assignee: The UAB Research Foundation
    Inventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman
  • Combinations of antibodies selective for DR5 and other therapeutic agents
    Patent number: 7704502
    Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: April 27, 2010
    Assignee: The UAB Research Foundation
    Inventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman, Jun Ohsumi, Albert F. LoBuglio, Donald J. Buchsbaum
  • ANTIBODY SELECTIVE FOR DR4 AND USES THEREOF
    Publication number: 20090208483
    Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of DR5 and DR4 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Application
    Filed: August 7, 2008
    Publication date: August 20, 2009
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventors: Tong Zhou, Robert P. Kimberly, William J. Koopman, Albert F. LoBuglio, Donald J. Buchsbaum
  • Combinations of Antibodies Selective for a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor and Other Therapeutic Agents
    Publication number: 20090022707
    Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Application
    Filed: May 22, 2007
    Publication date: January 22, 2009
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventors: Robert P. Kimberly, William J. Koopman, Albert F. LoBuglio, Tong Zhou, Donald J. Buchsbaum, Kimihisa Ichikawa, Jun Oshumi
  • Antibody selective for DR4 and uses thereof
    Patent number: 7476383
    Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of DR5 and DR4 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Grant
    Filed: October 31, 2002
    Date of Patent: January 13, 2009
    Assignee: The UAB Research Foundation
    Inventors: Tong Zhou, Robert P. Kimberly, William J. Koopman, Albert F. Lobuglio, Donald J. Buchsbaum
  • Combinations of DR5 antibodies and other therapeutic agents
    Patent number: 7279160
    Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Grant
    Filed: October 25, 2002
    Date of Patent: October 9, 2007
    Assignee: The UAB Research Foundation
    Inventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman, Jun Ohsumi, Albert F. Lobuglio, Donald J. Buchsbaum
  • Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
    Patent number: 7244429
    Abstract: An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Grant
    Filed: May 2, 2001
    Date of Patent: July 17, 2007
    Assignee: The UAB Research Foundation
    Inventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman
  • Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
    Publication number: 20030198637
    Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of DR5 and DR4 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Application
    Filed: October 31, 2002
    Publication date: October 23, 2003
    Inventors: Tong Zhou, Robert P. Kimberly, William J. Koopman, Albert F. LoBuglio, Donald J. Buchsbaum
  • Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
    Publication number: 20030190687
    Abstract: An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Application
    Filed: March 5, 2003
    Publication date: October 9, 2003
    Inventors: Tong Zhou, Kimihisa Ichikawa, Robert P Kimberly, William J Koopman
  • Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
    Publication number: 20030133932
    Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Application
    Filed: October 25, 2002
    Publication date: July 17, 2003
    Inventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman, Jun Ohsumi, Albert F. LoBuglio, Donald J. Buchsbaum